Predictive significance of T cell subset changes during

T lymphocyte phenotype advanced non-small cell lung cancer dendritic cell-cytokine-induced killer cell immunotherapy ex vivo culture regulatory T cells

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 30 05 2019
accepted: 06 06 2019
entrez: 3 12 2019
pubmed: 4 12 2019
medline: 4 12 2019
Statut: ppublish

Résumé

Adoptive T cell immunotherapy with cytokine-induced killer cells (CIKs) has been demonstrated to prolong the survival of patients with advanced non-small cell lung cancer (NSCLC). The aim of the present study was to evaluate whether the expansion of effector T cells and the decrease of regulatory T cells (Tregs) that occurred during the

Identifiants

pubmed: 31788044
doi: 10.3892/ol.2019.10964
pii: OL-0-0-10964
pmc: PMC6865835
doi:

Types de publication

Journal Article

Langues

eng

Pagination

5717-5724

Informations de copyright

Copyright: © Huang et al.

Références

Immunol Rev. 2014 May;259(1):245-58
pubmed: 24712470
Onco Targets Ther. 2017 Sep 22;10:4687-4690
pubmed: 29026316
Cancer Biother Radiopharm. 2017 Aug;32(6):221-226
pubmed: 28820635
Immunotherapy. 2017 Nov;9(14):1165-1174
pubmed: 29067881
Clin Cancer Res. 2017 Sep 1;23(17):5066-5073
pubmed: 28611200
J Immunol. 2007 Oct 1;179(7):4323-34
pubmed: 17878327
Cancer Immunol Immunother. 2014 Sep;63(9):939-46
pubmed: 24916038
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Immunology. 2015 Oct;146(2):185-93
pubmed: 26190355
Oncotarget. 2015 Aug 21;6(24):20278-87
pubmed: 26109430
Anticancer Res. 2017 Jul;37(7):3947-3954
pubmed: 28668899
Clin Transl Oncol. 2013 Oct;15(10):780-8
pubmed: 23359185
Oncotarget. 2017 Jan 24;8(4):7003-7013
pubmed: 27690294
Nat Rev Cancer. 2008 Apr;8(4):299-308
pubmed: 18354418
Oncoimmunology. 2016 Dec 7;6(4):e1264563
pubmed: 28507788
Cancer Lett. 2014 Feb 1;343(1):42-50
pubmed: 24045039
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Crit Rev Diagn Imaging. 1989;29(3):307-35
pubmed: 2667567
J Clin Invest. 2013 Jun;123(6):2447-63
pubmed: 23728179
J Immunol Res. 2015;2015:251657
pubmed: 26236751
Clin Transl Oncol. 2019 Jun;21(6):721-728
pubmed: 30374838
Cancer Immunol Immunother. 2005 Dec;54(12):1162-71
pubmed: 15889254
Oncotarget. 2015 Dec 1;6(38):41350-9
pubmed: 26462021
J Exp Med. 2007 Mar 19;204(3):547-57
pubmed: 17312008
Immunol Lett. 2017 Mar;183:37-43
pubmed: 28143792
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Immunity. 2015 Sep 15;43(3):579-90
pubmed: 26341400
J Exp Med. 2013 Oct 21;210(11):2435-66
pubmed: 24127486
J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10
pubmed: 20407789
Immunotherapy. 2017 Mar;9(5):411-421
pubmed: 28357913
Clin Cancer Res. 2019 Mar 1;25(5):1494-1504
pubmed: 30514775
Oncotarget. 2017 May 9;8(19):31318-31328
pubmed: 28412743

Auteurs

Lefu Huang (L)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 100038, P.R. China.

Guoliang Qiao (G)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 100038, P.R. China.

Michael A Morse (MA)

Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

Xiaoli Wang (X)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 100038, P.R. China.

Xinna Zhou (X)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 100038, P.R. China.

Jiangping Wu (J)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 100038, P.R. China.

Amy Hobeika (A)

Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

Jun Ren (J)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 100038, P.R. China.
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

Herbert K Lyerly (HK)

Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

Classifications MeSH